EUVIMEDEUVIMED entdecken
Crossref

Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk

Sona Sykorova, Jakub Krivy, Katarina Hadova, Anna Kekelakova, Peter Vavrinec, Diana Vavrincova-Yaghi

British Journal of Pharmacology · 2026-08 · 183 (15) · 4448-4470

DOI: 10.1111/bph.70469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 30.04.2026. Verfasst von Sona Sykorova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovak Republic. Hauptthemen laut MEDLINE: Kynurenic Acid, Kidney Diseases, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Ministry of Education, Science, Research and Sport of the Slovak Republic, Slovak Research and Development Agency, Ministerstvo školstva, vedy, výskumu a športu Slovenskej republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Renal fibrosis represents a common progressive outcome of various kidney injuries, yet no targeted therapies are currently available. Indoleamine‐2,3‐dioxygenase and its downstream metabolites, kynurenines (KYNs), modulate immune response and may contribute to tissue protection in inflammatory conditions. This study aimed to investigate the potential antifibrotic effects of KYN and kynurenic acid (KYNA). Experimental Approach The effects of KYN and KYNA were investigated in fibroblast culture and in a rat model of unilateral ureteral obstruction‐induced renal fibrosis. Key Results In vitro , both KYN and KYNA effectively inhibited TGF β ‐mediated fibrotic signalling. KYNA suppressed collagen I expression and myofibroblast transdifferentiation. In a rat model of unilateral ureteral obstruction, KYNA reduced fibrotic area, α ‐SMA‐positive regions as well as distal tubular dilatation in cortex and outer medulla. These reno‐protective effects were associated primarily with inhibition of the noncanonical TGF β pathway (pp38, pJNK/JNK) and modulation of the Wnt/ β ‐catenin and JAK2/STAT3 pathways. Furthermore, KYNA influenced proinflammatory NF‐ κ B p65 and shifted the IL‐17A/IL‐10 axis towards a Treg‐dominant profile. KYNA also enhanced fibroblast migration in vitro , suggesting a potential role in promoting wound healing under physiological conditions. Conclusion and Implications KYNA exerts antifibrotic effects both in vitro and in an in vivo model of renal fibrosis. The mechanisms involve multifaceted modulation of key signalling pathways related to fibrosis and immune response, highlighting KYNA as a promising therapeutic candidate for kidney fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kynurenic AcidKidney DiseasesKidneyAnimalsFibrosisMaleRatsTransforming Growth Factor betaUreteral ObstructionFibroblastsRats, Sprague-DawleySignal Transduction

Stichwörter der Autor:innen

TGFβ signallingindoleamine‐2,3‐dioxygenasekynurenic acidkynureninerenal fibrosisunilateral ureteral obstruction

Substanzen

Kynurenic AcidTransforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovak Republic.

Förderung

  • Ministry of Education, Science, Research and Sport of the Slovak Republic
  • Slovak Research and Development Agency
  • Ministerstvo školstva, vedy, výskumu a športu Slovenskej republiky
  • Agentúra na Podporu Výskumu a Vývoja

Zitieren

APA

Sykorova, S., Krivy, J., Hadova, K., Kekelakova, A., Vavrinec, P., & Vavrincova-Yaghi, D. (2026). Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk. British Journal of Pharmacology, 183(15), 4448-4470. https://doi.org/10.1111/bph.70469

Vancouver

Sykorova S, Krivy J, Hadova K, Kekelakova A, Vavrinec P, Vavrincova-Yaghi D. Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk. British Journal of Pharmacology. 2026;183(15):4448-4470. doi:10.1111/bph.70469

BibTeX
@article{Sykorova2026,
  author = {Sykorova, Sona and Krivy, Jakub and Hadova, Katarina and Kekelakova, Anna and Vavrinec, Peter and Vavrincova-Yaghi, Diana},
  title = {Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {15},
  pages = {4448--4470},
  doi = {10.1111/bph.70469}
}
Kostenlos starten →